Targeting tissue factor as an antithrombotic strategy

Seminars in Vascular Medicine

Volumn 3, Issue 2, 2003, Pages 205-213

  Golino, Paolo ^a   Cimmino, Giovanni ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Coagulation; Inactivated factor VII; Intracellular signaling; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

ACTIVE SITE INACTIVATED RECOMBINANT BLOOD CLOTTING FACTOR 7A; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; BLOOD CLOTTING INHIBITOR; CELL SURFACE PROTEIN; CHIMERIC PROTEIN; COMPLEMENTARY DNA; ENZYME PRECURSOR; FIBRONECTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MEMBRANE RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PLASMIN; PROCOAGULANT; PROTEIN INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 1; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIBOZYME; STRESS ACTIVATED PROTEIN KINASE; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL INJURY; CANCER; CELL PROLIFERATION; CELL TYPE; COMPLEX FORMATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; GENETIC TRANSFECTION; HEMOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN STRUCTURE; SEPSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TECHNIQUE; THROMBOGENESIS; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANIMALS; ARTERIOSCLEROSIS; BLOOD COAGULATION; FACTOR VIIIA; FIBRINOLYTIC AGENTS; HUMANS; LIPOPROTEINS; SIGNAL TRANSDUCTION; THROMBOPLASTIN; THROMBOSIS;

EID: 0041973835     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40679     Document Type: Article

References (83)

1. Dahlbäch B. Blood coagulation. Lancet 2000;355:1627-1632
2. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993;81:734-744
3. Nemerson V, Repke D. Tissue factor accelerates the activation of coagulation factor VII: the role of a high functional coagulation cofactor. Thromb Res 1985;40:351-358
4. Rao LV, Rapaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988;85:6687-6691
5. Radcliffe R, Nemerson V. Activation and control of factor VII by activated factor X and thrombin: isolation and characterization of a single chain form of factor VII. J Biol Chem 1975;250:388-395
6. Kisiel W, Fujikawa K, Davie EW. Activation of bovine factor VII (proconverlin) by factor XIIa (activated Hageman factor). Biochemistry 1977;16:4189-4194
7. Seligsohn U, Osterud B, Brown SF, Griffin JH, Rapaport SI. Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest 1979;64:1056
8. Masys DR, Bajaj SP, Rapaport SI. Activation of human factor VII by activated factors IX and X. Blood 1982;60:1143-1150
9. Tsujioka H, Suehiro A, Kakishita E. Activation of coagulation factor VII by tissue-type plasminogen activator. Am J Hematol 1999;61:34-39
10. Nakagaki T, Foster DC, Berkner KL, Kisiel W. Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry 1991;30:10819-10824
11. Neuenschwander PF, Fiore MM, Morrissey JH. Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism. J Biol Chem 1993;268:21489-21492
12. Sato Y, Asada Y, Marutsuka K, et al. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 1996;75:389-392
13. McNamara CA, Sarembock IJ, Backhuber BG, et al. Thrombin and vascular smooth muscle cells proliferation: implication for atherosclerosis and restenosis. Semin Thromb Hemost 1996;22:139-144
14. Broze GJ Jr, Leykam JE, Schwartz BD, Miletich JP. Purification of human brain tissue factor. J Biol Chem 1985;260:10917-10920
15. Paborsky LR, Tate KM, Harris RJ, et al. Purification of recombinant human tissue factor. Biochemistry 1989;28:8072-8077
16. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934-6938
17. Paborsky LR, Caras LW, Fisher KL, Gorman CM. Lipid association, but not the transmembrane domain, is required for tissue factor activity. Substitution of the transmembrane domain with a phosphatidylinositol anchor. J Biol Chem 1991;266:21911-21916
18. Pedersen AH, Nordfang O, Norris F, Willbeig FC, Christensen PM, Mueller KB. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 1990;265:16786-16793
19. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991;266:2158-2166
20. Payne MA, Neuenschwander PF, Johnson AE, Morrissey JH. Effect of soluble tissue factor on the kinetic mechanism of factor VIIa: enhancement of p-guanidinobenzoate substrate hydrolysis. Biochemistry 1996;35:7100-7106
21. Huang QL, Neuenschwander PF, Rezaie AR, Monrissey JH. Substrate recognition by tissue factor-factor VIta - evidence for interaction of residues Lys 165 and Lys 166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X. J Biol Chem 1996;271:21752-21757
22. Maynard JR, Dreyer BE, Stemerman MB, Pitlick FA. Tissue-factor coagulant activity of cultured human endothelial and smooth muscle cells and fibroblasts. Blood 1977;50:387-396
23. Drake TA, Rut W, Morrissey JH, Edgingtun TS. Functional tissue factor is entirely cell surface expressed on LPS stimulated human blood monocytes and a constitutively tissue factor producing neoplastic cell line. J Cell Biol 1989;109:389-395
24. Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci USA 1990;87:6995-6999
25. Balasubramanian V, Grabowsky E, Bini A, Nemerson Y. Platelets, circulating tissue factor, and fibrin colocalize ex vivo thrombi: real time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood 2002;100(8):2787-2792
26. Giesen PL, Rauch U, Bohrmann B, et al. Blood-born tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96:2311-2315
27. Wilcox JN, Smith KM, Schwartz S, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989;86:2839-2843
28. Jander S, Sitzer M, Wendt A, et al. Expression of tissue factor in high-grade carotid stenosis: association with plaque destabilization. Stroke 2001;32:850-854
29. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95:594-599
30. Annex BH, Denning SM, Channon KM, Sketch MH, Stack RS, Morrisey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995;91:619-622
31. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997;349:769-771
32. Ragni M, Golino P, Cirillo P, et al. Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury. Circulation 2000;102:113-117
33. Ravera A, Golino P, Piscione F, et al. Activation of tissue factor-dependent coagulation pathway in patients with acute myocardial infarction. J Am Coll Cardiol 2000;35(suppl A):406
34. Soejima H, Ogawa H, Yasue H, et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999;99:2908-2913
35. Soejima H, Ogawa H, Yasue H, et al. Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris. Thromb Res 1991;93:17-25
36. Asakura H, Kamikubo Y, Goto A, et al. Role of tissue factor in disseminated intravascular coagulation. Thromb Res 1995;80:217-224
37. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998;79:276-281
38. Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998;91:4216-4223
39. Levi M, ten Cate H, van der Poll T, Van Deventer SJ. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993;270:975-979
40. Fernandez PM, Rickles FR. Tissue factor and angiogenesis in cancer. Curr Opin Hematol 2002;9(5):401-406
41. Bokawera MI, Morrissey JH, Tarkowski A. Tissue factor as a proinflammatory agent. Arthritis Res 2002;4(3):190-195
42. Coughlin SR. Sol Sherry lecture in thrombosis: how thrombin 'talks' to cells: molecular mechanisms and roles in vivo. Arterioscler Thromb Vase Biol 1998;18:514-518
43. Camerer E, Huang W, Coughlm SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000;97:5255-5260
44. Petersen LC, Thastrup O, Hagel G, et al. Exclusion of known protease activated receptors in factor VIIa-induced signal transduction. Thromb Haemost 2000;83:571-576
45. Camerer E, Rortingen JA, Gjernes E, Larsen K, Skartlien AH, Iversen JG. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J Biol Chem 1999;274:32225-32233
46. Taniguchi T, Kakkar AK, Tuddenham EGD, Williamson RCN, Leinoine NR. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 1998;58:4461-4467
47. Prydz H. A new paradigm for blood coagulation research. Thromb Haemost 2000;83:520-522
48. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995;74:90-93
49. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995;6:S7-S13
50. Hamik A, Setiadi H, Bo GJ, McEver RP, Morrissey JH. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein. J Biol Chem 1999;274:4962-4969
51. Sevinsky JR, Rao LVM, Rut W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996;133:293-304
52. Ott I, Miyagi Y, Miyazaki K, Heeb MJ, Mueller BM, Rao LVM. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vase Biol 2000;20:874-882
53. Haskel EJ, Torr SR, Day KC, et al. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991;84:821-827
54. Jang Y, Guzman LA, Lincoff AM, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995;92:3041-3050
55. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997;96:646-652
56. St. Pierre J, Yang LY, Tamirisa K, et al. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler Thromb Vasc Biol 1999;19:2263-2268
57. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000;28:831-833
58. Golino P, Cirillo P, Calabrò P, Ragni M, D'Andrea D, Chiariello P. Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries. J Am Coll Cardiol 2001;38:569-576
59. Zoldhelyi P, Chen ZQ Shelat HS, McNatt JM, Willereson JT. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci USA 2000;98:4078-4083
60. Atsuchi N, Nishida T, Marutsuka K, Asada Y, Kamikubo Y, Takeshita A, Ueno H. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. Circulation 2001;103:570-575
61. Pawashe AB, Golino P, Ambrosio G, et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994;74:56-63
62. Ragni M, Cirillo P, Pascucci I, et al. A monoclonal antibody against tissue factor shortens tissue-plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 1996;93:1913-1920
63. Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 1996;35:266-272
64. Kondo S, Kisiel W. Regulation of factor VIIa in plasma: evidence that antithrombin III is the sole plasma proteinase inhibitor of human factor VIIa. Thromb Res 1987;46:325-331
65. Girard TJ, MacPhail LA, Likert KM, Novutny WF, Miletich JP, Bruze GJ Jr. Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein. Science 1990;248:1421-1424
66. Dennis MS, Lazarus RA. Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection. J Biol Chem 1994;269:22137-22144
67. Stassen JM, Lambeir A-M, Manhyssens G, Ripka WC, Nystrom A, Sixma JJ. Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties. Thromb Haemost 1995;74:646-654
68. Lee A, Agnelli G, Buller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in the prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2000;104:74-78
69. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and anti-lesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996;26:76-82
70. Himber B, Kirebbofer D, Riederer M, Tschopp TB, Steiner B, Roux SP. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 1997;78:1142-1149
71. Harker LA. Therapeutic inhibition of thrombin activities, receptors, and production. Hematol Oncol Clin North Am 1998;12:1211-1230
72. Golino P, Ragni M, Cirillo P, et al. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ Res 1998;82:39-46
73. Golino P, Cirillo P, D'Andrea D, et al. Long-term antithrombotic effects of human recombinant, active site-blocked factor VIIa in a chronic model of intravascular thrombosis (abstract). Circulation 1999;98:1727
74. Rao LVM, Ezban M. Active site-blocked activated factor VII as an effective antithrombotic agent: mechanism of action. Blood Coagul Fibrinolysis 2000;11:S135-S143
75. Marschall P, Thomson JB, Eckstein F, et al. Inhibition of gene expression with ribozyme. Cell Mol Neurobiol 1994;14:523-538
76. Cech TR. Self-splicing of group I introns. Annu Rev Biochem 1990;59:543-568
77. Symons RH. Small catalytic RNAS. Annu Rev Biochem 1992;61:641-671
78. Kiehntopf M, Esquivel EL, Brach MA, et al. Ribozyme: biology, biochemistry, and implication for clinical medicine. J Mol Med 1995;73:65-71
79. Cavusoglu E, Chen I, Rappaport J, Marmur JD. Inhibition of tissue factor gene induction and activity using a hairpin ribozyme. Circulation 2002;105(19):2282-2287
80. Feldman LJ, Sreg G. Optimal techniques for arterial gene transfer. Cardiovasc Res 1997;35:391-404
81. Brieger D, Topol E. Local drug delivery systems and prevention of restenosis. Cardiovasc Res 1997;35:405-413
82. Nabel EG. Gene therapy for cardiovascular disease. Circulation 1995;91:541-548
83. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239-4242